Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAIPAN Trial: Octreotide for Hereditary Hemorrhagic Telangiectasia–Related Gastrointestinal Bleeding
2018-004179-11Phase 3Active
- Sponsor
- Radboudumc
- Start
- May 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of octreotide in hereditary hemorrhagic telangiectasia (HHT) and gastrointestinal bleeding (2 arms), sponsored by Radboudumc. Primary endpoint: Successful response (transfusion requirement reduction). Started May 2019; status: active.
02
Drugs
octreotide
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)gastrointestinal bleeding
Beyond the preview
Go deeper on 2018-004179-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004179-11.